Q-omics provides the consensus-scored TFEB profile across patient tissues and cancer cell-line models. TFEB expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TFEB is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TFEB protein abundance shows 28,013 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where TFEB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFEB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFEB survival associations across molecular data types. TFEB RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFEB RNA expression–survival associations across cancer types. High TFEB expression shows unfavorable associations in LAML and READ, but favorable associations in KIRC, ACC, CESC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TFEB RNA expression.
This table summarizes TFEB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TFEB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFEB shows lower tumor expression in BLCA, LUAD, LUSC, THCA and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher TFEB RNA expression in normal versus tumor tissue (log2 FC = −1.530, t-test p < 0.001).
This table shows molecular features associated with TFEB in patient tissues and cancer cell lines. In patient samples, TFEB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TFEB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
